We found that decreased level of CSF clusterin was initially observed in amyloid-only pathology, which was considered as the earliest stage of AD, and elevated levels of CSF clusterin were observed in downstream tau pathology and neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.